Syncom Formulations India Ltd vs Zenlabs Ethica Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Syncom Formulations (India) Ltd is ₹ 13.73 as of 30 Apr 15:30 . The P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 yearsThe P/E Ratio of Zenlabs Ethica Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 years The Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 yearsThe Market Cap of Zenlabs Ethica Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 years The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The revenue of Zenlabs Ethica Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The ebitda of Zenlabs Ethica Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The net profit of Zenlabs Ethica Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Zenlabs Ethica Ltd changed from 33.21 % on March 2023 to 0 % on March 2025 . This represents a CAGR of -100.00% over 3 years .

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

About Zenlabs Ethica Ltd

Zenlabs Ethica Limited (Formerly known Neelkanth Technologies Limited) was incorporated in 1993.
The Company is one of the top 10 pharmaceutical contract marketing and trading companies in India that markets and distribute a wide range of branded drugs including Gastrointestinal disorders, Anti-Diabetics, Anti-Hypertensive Drugs, Anti-Infective, Soaps & Anti-Bacterial Drugs, Nutraceuticals, etc., It boasts of a comprehensive global network.
It deals into marketing and distribution of pharmaceutical products and has grown to be of India's top pharmaceutical companies in 2019. The Company has been launched in collaboration with Zenlabs Pharmaceutical Inc, Canada.
The strength lies in quality, affordable and branded drugs in enhancing the quality of life of people.
Apart from this, it offers more than 600 products across therapeutic segments, making it a leader among pharmaceutical companies in India.

FAQs for the comparison of Syncom Formulations (India) Ltd and Zenlabs Ethica Ltd

Which company has a larger market capitalization, Syncom Formulations (India) Ltd or Zenlabs Ethica Ltd?

Market cap of Syncom Formulations (India) Ltd is 1,290 Cr while Market cap of Zenlabs Ethica Ltd is 14 Cr

What are the key factors driving the stock performance of Syncom Formulations (India) Ltd and Zenlabs Ethica Ltd?

The stock performance of Syncom Formulations (India) Ltd and Zenlabs Ethica Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Syncom Formulations (India) Ltd and Zenlabs Ethica Ltd?

As of May 4, 2026, the Syncom Formulations (India) Ltd stock price is INR ₹13.73. On the other hand, Zenlabs Ethica Ltd stock price is INR ₹22.9.

How do dividend payouts of Syncom Formulations (India) Ltd and Zenlabs Ethica Ltd compare?

To compare the dividend payouts of Syncom Formulations (India) Ltd and Zenlabs Ethica Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.